Understanding Heart Damage from Ponatinib Cancer Medicine
Mitochondrial Dysfunction Underlies the Integrated Stress Response Activation in Ponatinib-Induced Cardiotoxicity
['FUNDING_R01'] · UNIVERSITY OF ARIZONA · NIH-11116951
This project explores why a cancer drug called ponatinib can harm the heart, aiming to find ways to protect patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ARIZONA (nih funded) |
| Locations | 1 site (TUCSON, UNITED STATES) |
| Trial ID | NIH-11116951 on ClinicalTrials.gov |
What this research studies
Ponatinib is a powerful cancer medicine used for chronic myeloid leukemia, but it can cause heart problems for some patients. This project aims to understand exactly how ponatinib affects heart cells, specifically looking at how the cell's energy factories (mitochondria) and stress responses are involved. By uncovering these detailed mechanisms, we hope to discover new ways to prevent or treat heart damage caused by this important cancer drug. This work could lead to safer treatments for people with CML.
Who could benefit from this research
Good fit: Patients with chronic myeloid leukemia who are taking or considering ponatinib and are concerned about heart side effects might benefit from future findings.
Not a fit: Patients not taking ponatinib or similar tyrosine kinase inhibitors for cancer would likely not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments or strategies to prevent heart damage in cancer patients taking ponatinib.
How similar studies have performed: While the specific role of the integrated stress response in ponatinib-induced cardiotoxicity is largely unknown, research into drug-induced cardiotoxicity and cellular stress responses is an active field.
Where this research is happening
TUCSON, UNITED STATES
- UNIVERSITY OF ARIZONA — TUCSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEE, WON HEE — UNIVERSITY OF ARIZONA
- Study coordinator: LEE, WON HEE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Burden